HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: Based on this trial, panobinostat demonstrated encouraging efficacy with good tolerability in MF and SS patients potentially making it an attractive alternative HDAC inhibitor in the treatment of CTCL.